Medicus Pharma Expands BCC Treatment Trials to UAE

Medicus Pharma Ltd. is expanding its groundbreaking research into non-invasive treatments for basal cell carcinoma (BCC) with a new clinical study in the UAE. The trial, known as SKNJCT-004, will take place at four top-tier medical institutions, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City, and will enroll 36 patients. The study will compare two dose levels of D-MNA, an investigational treatment, against a placebo to assess its efficacy and safety. Insights Research Organization and Solutions (IROS), a UAE-based clinical research firm, is coordinating the study, reinforcing the region’s growing role in global pharmaceutical innovation.

This expansion marks a major milestone in Medicus Pharma’s efforts to develop a first-in-class, non-invasive therapy for BCC, the most common form of skin cancer. A similar Phase 2 trial in the U.S., SKNJCT-003, has already enrolled over 50% of its targeted 60 patients, with interim data expected by Q1 2025. The company aims to leverage insights from both trials to fast-track regulatory approvals with the FDA and bring its treatment to market. CEO Dr. Raza Bokhari emphasized the UAE’s growing influence in pharma R&D, stating that this study will provide crucial data while advancing the company’s mission to deliver a safer, more effective treatment for BCC patients worldwide.